Gilead Sciences, Inc. (NASDAQ:GILD) Announces $0.77 Quarterly Dividend

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) declared a quarterly dividend on Thursday, April 25th, Zacks reports. Shareholders of record on Friday, June 14th will be given a dividend of 0.77 per share by the biopharmaceutical company on Thursday, June 27th. This represents a $3.08 dividend on an annualized basis and a yield of 4.71%. The ex-dividend date of this dividend is Friday, June 14th.

Gilead Sciences has increased its dividend payment by an average of 3.3% annually over the last three years and has increased its dividend annually for the last 9 consecutive years. Gilead Sciences has a payout ratio of 42.1% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Gilead Sciences to earn $7.27 per share next year, which means the company should continue to be able to cover its $3.08 annual dividend with an expected future payout ratio of 42.4%.

Gilead Sciences Stock Up 0.2 %

Shares of NASDAQ GILD traded up $0.15 during trading on Friday, reaching $65.42. The company had a trading volume of 12,382,425 shares, compared to its average volume of 6,443,315. Gilead Sciences has a 12-month low of $64.63 and a 12-month high of $87.86. The stock has a market cap of $81.45 billion, a PE ratio of 181.72, a P/E/G ratio of 1.17 and a beta of 0.19. The business's 50-day moving average is $71.28 and its 200 day moving average is $76.25. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts' consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 23.08% and a net margin of 1.76%. The firm had revenue of $6.69 billion for the quarter, compared to analysts' expectations of $6.36 billion. During the same period in the prior year, the firm posted $1.37 earnings per share. The company's quarterly revenue was up 5.3% on a year-over-year basis. As a group, equities analysts forecast that Gilead Sciences will post 4.2 earnings per share for the current fiscal year.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now owns 100,936 shares of the company's stock, valued at approximately $7,386,496.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Barclays cut their target price on Gilead Sciences from $85.00 to $80.00 and set an "equal weight" rating on the stock in a research note on Monday, February 12th. TD Cowen dropped their price objective on Gilead Sciences from $90.00 to $85.00 and set a "buy" rating on the stock in a research report on Friday. HSBC raised Gilead Sciences from a "reduce" rating to a "hold" rating and set a $69.00 target price on the stock in a research report on Wednesday. Oppenheimer reissued an "outperform" rating and issued a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Finally, Truist Financial cut Gilead Sciences from a "buy" rating to a "hold" rating and dropped their target price for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $83.87.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.